Medical

Million-dollar funding for macular disease research

Health Industry Hub | October 14, 2020 |
[Total: 1    Average: 5/5]

Medical News: Macular Disease Foundation Australia (MDFA) will award $1 million in its latest round of research funding and has also announced an additional new stream of grant funding to early-career researchers for “blue-sky” research in the field of macular disease.

MDFA Chairman Robert Kaye SC said research was the only hope to find cures for macular diseases, which cause half of all blindness and vision loss in Australia.

“MDFA has committed more than $4.1 million to world-leading Australian researchers since 2011. This year, we are proud to invest an additional $1 million to support research during these difficult economic times, which will be welcomed by Australian researchers and universities,” Mr Kaye said.

“This $1 million investment also makes MDFA the largest non-government source of research funds for macular disease in Australia. This commitment is in line with the National Strategic Action Plan for Macular Disease, which outlines Australia’s national response to macular disease and informs how limited health care resources can be better coordinated.

“Our aim continues to be to support the best research that works to reduce the incidence and impact of macular disease, and ultimately find better treatments and cures.”

Australian researchers can apply for funding from 8 October, World Sight Day, and the successful applicants will be announced in May 2021.

MDFA CEO Dee Hopkins said that as well as the $1 million on offer through the Research Grants Program, an additional stream of funding is available thanks to a generous bequest from a member of the macular disease community.

The Grant Family Fund will provide a total pool of $100,000 for creative and innovative projects by early-career Australian researchers. MDFA expects to award two grants of $50,000 for one-year projects commencing in 2021.

This new biennial grant opportunity will give preference to cutting-edge areas and approaches in macular disease research that require seed funding investment, explained Ms Hopkins.

The fund is named after Ronald Grant, who lived with age-related macular degeneration (AMD), and his daughter Faye Grant, who was his primary carer. Faye Grant made a substantial bequest to MDFA when she passed away in 2019 at the age of 59.

“We will use the Grant Family Fund to back highly innovative small-to-medium scale research projects for a year. These will be projects that show potential for future funding by granting bodies, in accordance with the principles of the National Health and Medical Research Council (NHMRC),” Ms Hopkins said.

Faye’s sister Janette Forrester said “In discussing it with MDFA, we thought that the research fund was the best way to use Faye’s bequest.”

Applications are now open and the successful applicants will be announced during Macular Disease Foundation Australia’s next Macula Month in May 2021.

Recipients of the $1 million Research Grants Program will be decided following rigorous evaluation, based largely on the NHMRC process, along with peer review, to ensure that the successful applicants meet the highest standards.

The Grant Review Panel encourages applications focused on these areas of strategic importance to MDFA:

  • dry age-related macular degeneration (pathogenesis; biomarkers /predictors of clinical course; treatments)
  • patient-oriented technological solutions for early detection and home monitoring and management of macular disease (using currently available devices and innovative technologies)
  • models of care and novel strategies to improve access to treatment and care, including strategies for Closing the Gap in macular health.

For more information on MDFA’s Research Grants Program, visit  www.mdfoundation.com.au/content/research-grants-program.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Medtronic recognised in the 2020 AFR BOSS most innovative health companies list

Medtronic recognised in the 2020 AFR BOSS most innovative health companies list

Health Industry Hub | October 23, 2020 |

MedTech News: Medtronic Australasia was proud to be recognised as one of Australia and New Zealand’s most innovative companies –ranking […]

More


News & Trends - Biotechnology

Biotech News - Ground-breaking COVID-19 test to not only identify virus but whether patient is infectious

Ground-breaking COVID-19 test to not only identify virus but whether patient is infectious

Health Industry Hub | October 23, 2020 |

Please log in to Health Industry Hub to view this content.
More


News & Trends - Pharmaceuticals

Pharma News - GSK confirms manufacturing site closure at end of 2022

GSK confirms manufacturing site closure at end of 2022

Health Industry Hub | October 22, 2020 |

Pharma News: In July 2020, GSK Australia announced to employees and stakeholders that the Boronia site in VIC would exit […]

More


Leadership & Management

Leadership Management Qualities - Creating the ‘light bulb moment’ on unconscious bias

Creating the ‘light bulb moment’ on unconscious bias

Health Industry Hub | October 21, 2020 |

Please log in to Health Industry Hub to view this content.
More